RANITIDINE- ranitidine hydrochloride tablet, film coated
VKT Pharma Private Limited
The active ingredient in Ranitidine Tablet USP, 150 mg / Ranitidine Tablet USP, 300 mg is Ranitidine hydrochloride (HCl), USP, a histamine H2 -receptor antagonist. Chemically it is N[2-[[[5-[(dimethylamino)methyl]-2-furanyl]methyl]thio]ethyl]-N’-methyl-2-nitro-1,1-ethenediamine, HCl. It has the following structure:
Ranitidine HCl is white to pale yellow, crystalline, practically odorless powder, sensitive to light and moisture. Melts at about 140°C with decomposition.
Each Ranitidine Tablet USP, 150 mg for oral administration contains 168 mg of Ranitidine HCl equivalent to 150 mg of ranitidine. Each tablet also contains the inactive ingredients microcrystalline cellulose, croscarmellose sodium, magnesium stearate, Opadry® 200 Orange 203A530006 (Polyvinyl alcohol, talc, titanium dioxide, glycerol monostearate, sodium lauryl sulphate, FD&C yellow 6 and iron oxide yellow), purified water.
Each Ranitidine Tablet USP, 300 mg for oral administration contains 336 mg of Ranitidine HCl equivalent to 300 mg of Ranitidine. Each tablet also contains the inactive ingredients microcrystalline cellulose, croscarmellose sodium, magnesium stearate, Opadry® 200 Yellow 203A520014 (Polyvinyl alcohol, talc, titanium dioxide, glycerol monostearate, sodium lauryl sulphate, FD&C yellow 5 and FD&C Blue 1), purified water.
Ranitidine Tablets is a competitive, reversible inhibitor of the action of histamine at the histamine H2 -receptors, including receptors on the gastric cells. Ranitidine Tablets does not lower serum Ca++ in hypercalcemic states. Ranitidine Tablets is not an anticholinergic agent.
Absorption: Ranitidine Tablets is 50% absorbed after oral administration, compared to an intravenous (IV) injection with mean peak levels of 440 to 545 ng/mL occurring 2 to 3 hours after a 150 mg dose. Absorption is not significantly impaired by the administration of food or antacids. Propantheline slightly delays and increases peak blood levels of Ranitidine, probably by delaying gastric emptying and transit time. In one study, simultaneous administration of high-potency antacid (150 mmol) in fasting subjects has been reported to decrease the absorption of Ranitidine Tablets.
Distribution: The volume of distribution is about 1.4 L/kg. Serum protein binding averages 15%.
Metabolism: In humans, the N-oxide is the principal metabolite in the urine; however, this amounts to < 4% of the dose. Other metabolites are the S-oxide (1%) and the desmethyl ranitidine (1%). The remainder of the administered dose is found in the stool. Studies in patients with hepatic dysfunction (compensated cirrhosis) indicate that there are minor, but clinically insignificant, alterations in ranitidine half-life, distribution, clearance, and bioavailability.
Excretion: The principal route of excretion is the urine, with approximately 30% of the orally administered dose collected in the urine as unchanged drug in 24 hours. Renal clearance is about 410 mL/min, indicating active tubular excretion. The elimination half-life is 2.5 to 3 hours. Four patients with clinically significant renal function impairment (creatinine clearance 25 to 35 mL/min) administered 50 mg of ranitidine intravenously had an average plasma half-life of 4.8 hours, a Ranitidine clearance of 29 mL/min, and a volume of distribution of 1.76 L/kg. In general, these parameters appear to be altered in proportion to creatinine clearance (see DOSAGE AND ADMINISTRATION).
Geriatrics: The plasma half-life is prolonged and total clearance is reduced in the elderly population due to a decrease in renal function. The elimination half-life is 3 to 4 hours. Peak levels average 526 ng/mL following a 150-mg twice-daily dose occur in about 3 hours (see PRECAUTIONS: Geriatric Use and DOSAGE AND ADMINISTRATION: Dosage adjustment for Patients with impaired renal function).
Pediatrics: There are no significant differences in the pharmacokinetic parameter values for ranitidine in pediatric patients (from one month upto 16 yrs of age) and healthy adults when correction is made for body weight. The average bioavailability of Ranitidine is given orally to pediatric patients is 48%, which is comparable to the bioavailability of Ranitidine in the adult population. All other pharmacokinetic parameter values (t1/2, Vd, and CL) are similar to those observed with intravenous Ranitidine use in pediatric patients. Estimates of Cmax and Tmax are displayed in Table 1.
|Population (age)||n||Dosage Form (dose)||Cmax (ng/mL)||Tmax (hours)|
|Gastric or duodenal ulcer (3.5 to 16 years)||12||Tablets (1 to 2 mg/ kg)||54 to 492||2.0|
Plasma clearance measured in 2 neonatal patients (less than 1 month of age) was considerably lower (3 mL/min/kg) than children or adults and is likely due to reduced renal function observed in this population (see PRECAUTIONS: Pediatric Use and DOSAGE AND ADMINISTRATION: Pediatric use).
Pharmacodynamics: Serum concentrations necessary to inhibit 50% of stimulated gastric acid secretion are estimated to be 36 to 94 ng/mL. Following a single oral dose of 150 mg, serum concentrations of ranitidine are in this range up to 12 hours. However, blood levels bear no consistent relationship to dose or degree of acid inhibition.
Antisecretory Activity: 1. Effects on Acid Secretion: Ranitidine Tablets inhibits both daytime and nocturnal basal gastric acid secretions as well as gastric acid secretion stimulated by food, betazole, and pentagastrin, as shown in below table 2.
|Time After Dose, hours||% Inhibition of Gastric Acid Output by Dose, mg|
|75 – 80||100||150||200|
|Basal||Up to 4||99||95|
|Nocturnal||Up to 13||95||96||92|
|Betazole||Up to 3||97||99|
|Pentagastrin||Up to 5||58||72||72||80|
|Meal||Up to 3||73||79||95|
It appears basal-, nocturnal-, and betazole- stimulated secretions are most sensitive to inhibition by Ranitidine Tablets responding almost completely to doses of 100 mg or less, while pentagastrin- and food-stimulated secretions are more difficult to suppress.
2. Effects on other gastrointestinal secretions:
Pepsin: Oral Ranitidine Tablets does not affect pepsin secretion. Total pepsin output is reduced in proportion to the decrease in volume of gastric juice.
Intrinsic Factor: Oral Ranitidine Tablets has no significant effect on pentagastrin-stimulated intrinsic factor secretion.
Serum Gastrin: Ranitidine Tablets has little or no effect on fasting or postprandial serum gastrin.
Other Pharmacologic Actions:
- Gastric bacterial flora-increase in nitrate-reducing organisms, significance not known.
- Prolactin levels-no effect in recommended oral or IV dosage, but small, transient, dose-related increases in serum prolactin have been reported after IV bolus injections of 100 mg or more.
- Other pituitary hormones-no effect on serum gonadotropins, TSH or GH. Possible impairment of vasopressin release.
- No change in cortisol, aldosterone, androgen or estrogen levels.
- No anti androgenic action.
- No effect on count, motility or morphology of sperm.
Clinical Trials: Active Duodenal Ulcer: In a multicenter, double-blind, controlled, US study of endoscopically diagnosed duodenal ulcers, earlier healing was seen in patients treated with Ranitidine Tablets as shown in Table 3.
|Ranitidine Tablets *||Placebo *|
|Number Entered||Healed/ Evaluable||Number Entered||Healed/ Evaluable|
|Outpatients||195||69/182 (38%)†||188||31/164 (19%)|
|Week 4||137/187 (73%)†||76/168 (45%)|
|Ulcer Healed||Ulcer Not Healed|
Foreign studies have shown that patients heal equally well with 150 mg twice daily and 300 mg at bedtime (85% versus 84%, respectively) during a usual 4-week course of therapy. If patients require extended therapy of 8 weeks, the healing rate may be higher for 150 mg twice daily as compared to 300 mg at bedtime (92% versus 87%, respectively).
Studies have been limited to short-term treatment of acute duodenal ulcer. Patients whose ulcers healed during therapy had recurrences of ulcers at the usual rates.
Maintenance therapy in duodenal ulcer: Ranitidine has been found to be effective as maintenance therapy for patients following healing of acute duodenal ulcers. In 2 independent, double-blind, multi-center, controlled trials, the number of duodenal ulcers observed was significantly less in patients treated with Ranitidine Tablets (150 mg at bedtime) than in patients treated with placebo over a 12-month period.
% = Life table estimate.
RAN = ranitidine
PLC = Placebo.
|Double-Blind, Multicenter, Placebo-Controlled Trials|
|Duodenal Ulcer Prevalence|
|Multicenter Trial||Drug||0-4 Months||0-8 Months||0-12 Months||No. of Patients|
As with other H2 -antagonists, the factors responsible for the significant reduction in the prevalence of duodenal ulcers include prevention of recurrence of ulcers, more rapid healing of ulcers that may occur during maintenance therapy, or both.
Gastric Ulcer: In a multicentre, double-blind, controlled, US study of endoscopically diagnosed gastric ulcers, earlier healing was seen in the patients treated with Ranitidine Tablets as shown in Table 6.
|Ranitidine Tablets *||Placebo *|
|Number entered||Healed / Evaluable||Number entered||Healed / Evaluable|
|Outpatients||92||16/83 (19%)||94||10/83 (12%)|
|Week 6||50/73 (68%)†||35/69 (51%)|
Maintenance of healing Gastric Ulcers: In 2 multicentre, double-blind, randomized, placebo-controlled, 12-month trials conducted in patients whose gastric ulcers had been previously healed, Ranitidine Tablets 150 mg at bed time was significantly more effective than placebo in maintaining healing of gastric ulcers.
Pathological Hypersecretory Conditions (such as Zollinger-Ellison syndrome): Ranitidine Tablets inhibits gastric acid secretion and reduces occurrence of diarrhea, anorexia, and pain in patients with pathological hypersecretion associated with Zollinger- Ellison syndrome, systemic mastocytosis, and other pathological hypersecretory conditions. (eg. Postoperative, “short-gut” syndrome, idiopathic). Use of Ranitidine Tablets was followed by healing of ulcers in 8 of 19 (42%) patients who were intractable to previous therapy.
Gastroesophageal Reflux Disease (GERD): In 2 multicenter, double-blind, placebo-controlled, 6-week trials performed in the United States and Europe, ranitidine tablets USP, 150 mg twice daily was more effective than placebo for the relief of heartburn and other symptoms associated with GERD. Ranitidine- treated patients consumed significantly less antacid than did placebo- treated patients.
The US trial indicated that Ranitidine Tablets USP, 150 mg twice daily significantly reduced the frequency of heartburn attacks and severity of heartburn pain within 1 to 2 weeks after starting therapy. The improvement was maintained throughout the 6-week trial period. Moreover, patient response rates demonstrated that the effect of heartburn extends through both the day and night time periods.
In 2 additional US multicenter, double-blind, placebo- controlled, 2- week trials, Ranitidine Tablets USP, 150 mg twice daily was shown to provide relief of heartburn pain within 24 hours of initiating therapy and a reduction in the frequency of severity of heartburn.
Erosive Esophagitis: In 2 multicenter, double- blind, randomized, placebo- controlled, 12- week trials performed in the United States, Ranitidine Tablets USP, 150 mg 4 times daily was significantly more effective than placebo in healing endoscopically diagnosed erosive esophagitis and in relieving associated heartburn. The erosive esophagitis healing rates were as follows:
|Placebo * n = 229||Ranitidine Tablets USP, 150 mg 4 times daily * n = 215|
|Week 4||43/198 (22%)||96/206 (47%)†|
|Week 8||63/176 (36%)||142/200 (71%)†|
|Week 12||92/159 (58%)||162/192 (84%)†|
Maintenance of Healing of Erosive Esophagitis: In 2 multicenter, double-blind, randomized, placebo-controlled, 48-week trials conducted in patients whose erosive esophagitis had been previously healed, Ranitidine Tablets USP, 150 mg twice daily was significantly more effective than placebo in maintaining healing of erosive esophagitis.
All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.